Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma

Neuro-Oncology

Volumn 9, Issue 3, 2007, Pages 370-372

  Wavre, Aurelia ^a   Baur, Audrey S ^b   Betz, Michael ^a   Mühlematter, Dominique ^c   Jotterand, Martine ^c   Zaman, Khalil ^a   Ketterer, Nicolas ^a,c  

^a Department of Oncology ^*  (Switzerland)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Central nervous system involvement; Multiple myeloma; p53 deletion

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; ARTICLE; BRAIN CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOMAL INSTABILITY; CYTOGENETICS; FATALITY; FOCAL EPILEPSY; GENE DELETION; HUMAN; HUMAN TISSUE; MALE; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMACYTOMA; PROGNOSIS;

BRAIN NEOPLASMS; DIABETES MELLITUS, TYPE 2; FATAL OUTCOME; GENE DELETION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLASMACYTOMA;

EID: 34547479977     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2007-008     Document Type: Article

References (5)

1. Fassas AB, Muwalla F, Berryman T, et al. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations. Br J Haematol. 2002;117:103-108.
2. Chang H, Sloan S, Li D, Keith SA. Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. Br J Haematol. 2004;127:280-284.
3. Fassas AB, Ward S, Muwalla F, et al. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma. 2004;45:291-300.
4. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;10:4569-4575.
5. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802-809.